Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium zirconium cyclosilicate vs insulin-glucose for acute hyperkalemia in maintenance hemodialysis
ChiCTR2100046689Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sodium zirconium cyclosilicate in hyperkalemia and end-stage kidney disease (ESKD) (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Serum potassium. Started Jun 2021; status: recruiting.
02
Drugs
sodium zirconium cyclosilicate
03
Conditions
hyperkalemiaend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on ChiCTR2100046689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046689.